Orthobiologics for Bone Repair and Regeneration

Sales of Orthobiologics for the Repair and Regeneration of Bone Totaled Nearly $2.4bn in 2018, with Sales Expected to Climb at a CAGR of 3.2% through 2024.

Highlights

• Over the forecast period covered by this report, the market for orthobiologics for the repair and regeneration of bone is projected to increase at a CAGR of 3.2%, from approximately $2,358.0m in 2018 to $2,844.2m in 2024.
• This report comprises three market segments; allografts and synthetic grafts, growth factors, and cellular bone matrices (CBMs). Of the three segments, allografts and synthetic grafts contributed the greatest proportion (59%) of revenue in 2018, followed by growth factors (26%), and CBMs (15%).

• Key drivers of the market for orthobiologics for the repair and regeneration of bone include:
  • The ageing of the population and the global burden of musculoskeletal disease
  • Increases in spinal fusion and arthroplasty procedure volumes
  • The use of orthobiologics, such as growth factors, that demonstrate a reduction in revision surgery rates
  • Clinical outcomes that show superiority to autograft in regard to safety/efficacy
  
  

• Factors that will constrain growth in the global market for orthobiologics for bone repair and regeneration include:
  • The high price of premium products such as growth factors and CBMs
  • Limited reimbursement for certain CBM products
  • A hesitance in certain countries to use human-based tissue for bone grafts
  • Highly competitive markets, particularly for allografts and synthetic grafts
  
  

• Leading competitors in this market include Medtronic, MTF Biologics, NuVasive, and Orthofix.

Key topics covered

• An overview of key clinical applications for orthobiologics for bone repair
• Spinal fusion procedure volumes forecast, by country/region
• Products offered by leading manufacturers
• Global market forecasts, by region
• In-depth market and competitive analyses

Overview

Growth in this market will be driven by the ageing of the population and the global burden of musculoskeletal disease. Market growth will also be aided by clinical outcomes that show superiority to autograft in regard to safety/efficacy. Of the market segments included within this analysis, allografts and synthetic grafts contributed the greatest proportion (59%) of revenue in 2018, followed by growth factors (26%), and cellular bone matrices (15%).

This analysis includes a discussion of products, current/forecast markets, and competitors in the global markets for orthobiologics for the repair and regeneration of bone. Market forecasts and spinal fusion procedure volumes are provided for the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World for 2018-24.